Compare Barrick Gold Corp (B) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs BioNano Genomics Inc — how do they compare? Barrick Gold Corp trades at $41.25 (market cap $65.92B), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: Barrick Gold Corp is far larger — about 4825.8× BioNano Genomics Inc's market cap, and Barrick Gold Corp pays a 1.74% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| B | BNGO | |
|---|---|---|
Market Cap | $65.92B | $13.66M |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $4.92 |
52-Week Low | $23.50 | $1.06 |
Enterprise Value | $64.67B | $16.26M |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $40.91, down 6.36% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $40 and resistance at $42, while recent developments include a $1.95 billion settlement with Newmont and plans for a North American gold IPO. Revenue growth accelerated to $17.0 billion in 2025 with net income reaching $5.0 billion, supported by a 31.6% net margin.
The outlook remains positive with 66.7% analyst buy ratings and a $49.83 consensus price target representing 22% upside. Key risks include gold price volatility and execution of the planned IPO, but strong cash flow generation and debt reduction provide stability for continued shareholder returns through dividends and potential buybacks.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
